Literature DB >> 8866908

Prevalence of insulin resistance in essential hypertension.

L Lind1, C Berne, H Lithell.   

Abstract

OBJECTIVE: To establish the prevalence of insulin resistance in hypertensive subjects. DESIGN AND METHODS: The euglycaemic hyperinsulinaemic clamp was performed in 420 hypertensive patients taking no antihypertensive medication and in 51 age- and sex-matched healthy controls. No subjects with known diabetes mellitus or fasting hyperglycaemia were included in the study.
RESULTS: The mean value for insulin-mediated glucose uptake (M-value at clamp) in the healthy control group (8.2 mg/kg per min) -2 SD was chosen as the cutoff limit for insulin resistance (4.4 mg/kg per min). At this cutoff limit, 27% of the hypertensive subjects were insulin resistant (mean value 3.1 mg/kg per min in this group, range 0.7-4.3). A similar prevalence of insulin resistance in hypertensive patients was found (31%) if the 95th percentile of the non-normally distributed insulin sensitivity index (M/I at clamp) was used to define the cutoff limit for insulin resistance: (4.4 mg/kg per min)/(mU/l x 100). In the insulin-resistant group, 50% showed elevated levels of serum triglycerides (> 2.0 mmol/l), 50% had abdominal obesity (waist:hip ratio > 0.95), 20% had elevated levels of serum uric acid (> 400 mumol/l) and 48% had low high-density lipid (HDL)-cholesterol levels (< 1.0 mmol/l). Half of the insulin-resistant hypertensives but only 20% of the non-insulin resistant group had two or more of these other four metabolic impairments (P < 0.001). Insulin resistance in hypertension was also associated with an increased heart rate (+3 beats/min faster than in non-insulin resistant hypertensive patients, P < 0.01), but no significant differences in blood pressure were found between insulin resistant and non-insulin resistant hypertensive patients.
CONCLUSION: When insulin resistance was defined as an M-value at clamp of < 4.4 mg/kg per min, based on calculations from a healthy control sample, about 25% of a sample of hypertensive subjects, taking no antihypertensive treatment and with no history of diabetes mellitus or hyperglycaemia, was found to be insulin resistant. This group of insulin-resistant hypertensives also displayed a high degree of clustering of other metabolic impairments.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8866908

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  19 in total

Review 1.  Obesity-related hypertension: role of the sympathetic nervous system, insulin, and leptin.

Authors:  Kazuko Masuo
Journal:  Curr Hypertens Rep       Date:  2002-04       Impact factor: 5.369

2.  Two groups were different in cardiovascular risk study.

Authors:  Malvinder S Parmar
Journal:  BMJ       Date:  2003-08-02

3.  The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients.

Authors:  R Negro; G Formoso; H Hassan
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

Review 4.  Antihypertensive drugs and glucose metabolism.

Authors:  Christos V Rizos; Moses S Elisaf
Journal:  World J Cardiol       Date:  2014-07-26

Review 5.  Hypertension in postmenopausal women: pathophysiology and treatment.

Authors:  Chiara Leuzzi; Maria Grazia Modena
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-03-01

6.  Diagnosis of insulin resistance in hypertensive patients by the metabolic syndrome: AHA vs. IDF definitions.

Authors:  C-M Hwu; C A Hsiung; K-D Wu; W-J Lee; K-C Shih; J Grove; Y-D I Chen; B L Rodriguez; J D Curb
Journal:  Int J Clin Pract       Date:  2008-06-28       Impact factor: 2.503

7.  Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension.

Authors:  Sarah F Knight; Jianghe Yuan; Siddhartha Roy; John D Imig
Journal:  Am J Physiol Renal Physiol       Date:  2009-11-11

8.  Endothelial dysfunction and the development of renal injury in spontaneously hypertensive rats fed a high-fat diet.

Authors:  Sarah F Knight; Jeffrey E Quigley; Jianghe Yuan; Siddhartha S Roy; Ahmed Elmarakby; John D Imig
Journal:  Hypertension       Date:  2007-12-24       Impact factor: 10.190

Review 9.  Antihypertensive medications and their effects on lipid metabolism.

Authors:  Mrunalini Deshmukh; Ho Won Lee; Samy I McFarlane; Adam Whaley-Connell
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

Review 10.  The improvement of hypertension by probiotics: effects on cholesterol, diabetes, renin, and phytoestrogens.

Authors:  Huey-Shi Lye; Chiu-Yin Kuan; Joo-Ann Ewe; Wai-Yee Fung; Min-Tze Liong
Journal:  Int J Mol Sci       Date:  2009-08-27       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.